RETRACTED ARTICLE: Long-Term Safety Analysis of the BBV152 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India

Kaur, Upinder; Jaiswal, Aakanksha; Jaiswal, Ayushi; Singh, Kunal; Pandey, Aditi; Chauhan, Mayank; Rai, Mahek; Kansal, Sangeeta; Patwardhan, Kishor; Jaisawal, Vaibhav; Chakrabarti, Sankha Shubhra

doi:10.1007/s40264-024-01432-6

Drug Saf

2024

DOI: 10.1007/s40264-024-01432-6

|View full text |Cite|

RETRACTED ARTICLE: Long-Term Safety Analysis of the BBV152 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India

Upinder Kaur,

Aakanksha Jaiswal,

Ayushi Jaiswal

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

Zhao,

Li,

Tian

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe efficacy of coronavirus disease 2019 (COVID‐19) vaccines in preventing SARS‐CoV‐2 infection in patients with hepatocellular carcinoma (HCC) is not clear.MethodsFrom January 2022 to October 2022, patients diagnosed with HCC in a prospective, multicenter, observational cohort were analyzed.ResultsOne hundred and forty‐one patients with (n = 107) or without COVID‐19 vaccination (n = 34) were included. The number of patients with severe or very severe infection was relatively lower in the vaccinated group (3.7% vs. 11.8%, p = 0.096). Median infection‐free survival in the vaccinated group (14.0 vs. 8.3 months, p = 0.010) was significantly longer than that in the unvaccinated group. COVID‐19 vaccination (hazard ratio (HR) HR = 0.47), European Cooperative Oncology Group performance score = 0 (HR = 2.06), and extrahepatic spread (HR = 0.28) were found to be the independent predictive factors for infection‐free survival.ConclusionCOVID‐19 vaccines could effectively reduce the SARS‐Cov‐2 infection in patients with HCC.

show abstract

Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

Zhao,

Li,

Tian

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

BBV-152 COVID-19 vaccine-related AESIs may persist for a year

2024

Reactions Weekly

View full text Add to dashboard Cite

Study on adverse effects following Covaxin stirs heated debate in India

Lal

2024

BMJ

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

RETRACTED ARTICLE: Long-Term Safety Analysis of the BBV152 Coronavirus Vaccine in Adolescents and Adults: Findings from a 1-Year Prospective Study in North India

Cited by 5 publications

References 13 publications

Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

BBV-152 COVID-19 vaccine-related AESIs may persist for a year

Study on adverse effects following Covaxin stirs heated debate in India

Contact Info

Product

Resources

About